Irreversible steroid aromatase inhibitor, similar in structure to the natural substance – androstenedione.
In postmenopausal women, estrogens are produced primarily by converting androgens to estrogens under the action of the aromatase enzyme in peripheral tissues. Blocking the formation of estrogen by inhibiting aromatase is an effective and selective method for treating hormone-dependent breast cancer in postmenopausal women. The mechanism of action of the drug Aromazin ® is due to the fact that it irreversibly binds to the active fragment of the enzyme, causing its inactivation. In postmenopausal women, Aromazin ® significantly reduces serum estrogen concentration, starting at a dose of 5 mg, with a maximum reduction (> 90%) achieved with doses of 10-25 mg. In postmenopausal patients with breast cancer who received 25 mg of the drug daily
Dosing and Administration
Inside, preferably after a meal. Adults and patients of advanced age – 25 mg once a day.
In patients with early breast cancer, treatment with the drug is recommended to continue until the total duration of successive adjuvant hormone therapy reaches 5 years. Treatment of patients with advanced breast cancer is long. If signs of progression of the tumor or signs of contralateral breast cancer appear, treatment with Aromazin ® should be discontinued.
In patients with hepatic or renal insufficiency, dose adjustments are not required.
Not recommended for use in children.